Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

Sponsor
Methodist Health System
Study ID
NCT06222437
Phase
PHASE1
Status
Withdrawn

Conditions

  • Polycystic Ovary Syndrome

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 45 Years
Healthy Volunteers
Not accepted

Interventions

  • Semaglutide — DRUG
    effectiveness of semaglutide in PCOS

Study Details

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Key Dates

Start date
Feb 28, 2026
Status verified
Jan 2026
Primary completion
Feb 28, 2026
Completion
Feb 28, 2027

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Protocol group
    PCOS women in the age 18 to 45 years

Primary Outcome Measure

Number of appropriate weekly dose [ Time Frame: 4 weeks ]

Related Studies